- Company
- Pharmaceutical exports continue to be sluggish...
- by Kim, Jin-Gu Mar 20, 2023 05:51am
- Domestic drugs are continuing to show sluggish sales overseas. During the prolonged COVID-19 crisis, Korea enjoyed an uprise in pharmaceutical exports, but due to the nearing endemic, exports are returning to the pre-COVID-19 level. In particular, the sharp drop in exports of COVID-19 vaccines manufactured in Korea affected the decline in Kor
- Company
- Leclaza costs 88 billion won for phase 3 in 3 years
- by Chon, Seung-Hyun Mar 20, 2023 05:51am
- Last year, Yuhan invested a total of 88 billion won in phase 3 clinical trial of Leclaza, a new anti-cancer drug. Yuhan Corporation is challenging the first-line treatment approval based on the efficacy and safety of Leclaza confirmed in clinical trials. According to the Financial Supervisory Service on the 20th, as of the end of last year, Yuha
- Company
- Possibility of passing the drug price reduction Act
- by Kim, Jin-Gu Mar 20, 2023 05:51am
- A sense of crisis in the biopharmaceutical industry is rising as the possibility of passing the 'drug price reduction/refund bill' in the plenary session of the National Assembly is increasing. The pharmaceutical industry is concerned that the amendment will infringe on the right to request a trial as stipulated in the Constitution, and furt
- Company
- Generics for Visanne grew significantly in Bayer's opening
- by Whang, byung-woo Mar 17, 2023 05:46am
- As the generic market for Visanne, Bayer's endometriosis treatment, is growing rapidly, the status of the original drug is being threatened. According to the pharmaceutical industry, as the number of patients with endometriosis increased significantly, the treatment market was also found to be growing significantly. Looking at the health
- Company
- Sales in the Dutasteride market are strong
- by Kim, Jin-Gu Mar 17, 2023 05:46am
- The original drug, GSK Avodart, was the first in 2021 to go beyond Propecia (Finasteride), leading to the market for two consecutive years until last year. In the case of generic, Dutasteride grows steeply and pursues the Finesteride quickly. In the pharmaceutical industry, the new formulation product is cited as a variable in the market. Bo
- Company
- Enhertu's petition subcommittee is announced
- by Eo, Yun-Ho Mar 17, 2023 05:46am
- The 'answer' to the national petition urging insurance coverage for the next-generation ADC anti-cancer drug Enhertu is expected to come out soon. According to the related industry, Daiichi Sankyo Korea and AstraZeneca Korea's HER2-positive breast cancer treatment, Antibody-drug conjugate (ADC) Enhertu, will be submitted to the Petition Revi
- Company
- MSD ‘Januvia’s NTTP impurity level is at low risk’
- by Jung, Sae-Im Mar 17, 2023 05:45am
- On the 16th, Regarding the issue of excess nitrosamine impurities detected in some Januvia 50mg products, MSD Korea said, “The company has detected impurities that exceed the acceptable limit in two 50mg packaged batches among all Januvia products that were imported to Korea until October 2022. As a precautionary measure, the company has de
- Company
- Exclusive domestic sales of JW Shinyak, Galderma hair loss
- by Mar 16, 2023 05:45am
- JW Shinyak announced on the 15th that it has signed a domestic exclusive sales contract with Galderma for hair loss treatment Ell-cranell and nail athlete's foot treatment Loceryl nail lacquer. According to the contract, JW Shinyak will be in charge of domestic sales and marketing of the two products. Ell-cranell is an androgenetic alopecia t
- Company
- SPC Korea to exclusively distribute 2 new COPD drugs in KOR
- by Eo, Yun-Ho Mar 16, 2023 05:45am
- SPC Korea will now be in charge of the domestic supply of two new COPD drugs in Korea. The company announced it had signed an exclusive agreement for the sales and distribution of two Chronic Obstructive Pulmonary Disease (COPD) treatments with the multinational pharmaceutical company, Covis Pharma GmbH. Under the agreement, SPC Pharm has
- Company
- IIT seeks use of Leclaza in the first line in Korea
- by Jin-Joong Hwang Mar 15, 2023 05:56am
- Investigator-Initiated trials (IIT) are being conducted on the use of ‘Leclaza (lasertinib),’ Yuhan Corp’s new third-generation drug for non-small-cell lung cancer (NSCLS), as a first-line treatment. Over the past 3 years, a total of 11 IITs have been approved for Leclaza, indicating the high interest among HCPs in finding a new treatment
